GlassScriptPhysician profile
Darrin D Menard
NPI 1417982422
$13,027.37
in general payments reported to CMS, 2019-2025
55 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,720 · 2020: $1,783 · 2021: $1,986 · 2022: $1,862 · 2023: $1,858 · 2024: $1,854 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,676.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,833.64 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,801.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,212.19 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,154.74 | 2021-2025 | |
| Amgen INC. | $787.40 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $733.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $568.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $541.89 | 2019-2023 | Trintellix |
| Antares Pharma, INC. | $388.82 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $335.38 | 2020-2025 | Veozah |
| Corium, LLC | $321.66 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $299.41 | 2019-2025 | Capvaxive, Belsomra, Gardasil 9 |
| Amarin Pharma, INC. | $248.73 | 2019-2021 | |
| Allergan, INC. | $213.62 | 2019-2020 | |
| Esperion Therapeutics, INC. | $196.26 | 2021-2025 | Nexletol |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrin Menard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.